Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Conference Call to Discuss its Results for Six-Month Period and Quarter Ended December 31
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 17, 2017 , to discuss ImmunoGen's
View HTML
Toggle Summary ImmunoGen Announces Departure of Sandra Poole
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations and Commercial Development, will leave the Company at
View HTML
Toggle Summary ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results in Platinum-Resistant Ovarian Cancer Published in the Journal of Clinical Oncology
Positive Results Form Basis for FORWARD I Phase 3 Registration Trial WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase 1 expansion cohort
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at the 35th Annual J. P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy , President and CEO, will present at the upcoming 35 th Annual J. P.
View HTML
Toggle Summary Preclinical Data on IMGN632, a Novel CD123-Targeting ADC, Presented at ASH Annual Meeting
Data Demonstrate Activity in Acute Myeloid Leukemia Models While Sparing Normal Bone Marrow WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that preclinical data on IMGN632
View HTML
Toggle Summary ImmunoGen to Present Preclinical Data Highlighting Potential of Combining Mirvetuximab Soravtansine with an Immune Checkpoint Inhibitor at SITC 2016 Annual Meeting
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with
View HTML
Toggle Summary ImmunoGen Announces Preclinical Data Presentations for Two ADCs With Novel IGN Payloads at Upcoming 58th ASH Annual Meeting
Includes Oral Presentation on CD123-Targeting ADC IMGN632 WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company's novel IGN ADCs,
View HTML
Toggle Summary ImmunoGen Reports Financial Results for Quarter Ended September 30 and Reviews Business Highlights
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine On Track to Begin before Year End FORWARD II Trial Assessing Mirvetuximab Soravtansine Combinations with Avastin ® , Carboplatin, Doxil ® , and Keytruda ® Ongoing Strategic Review Completed to Strengthen Underlying Business and Drive Long-term
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Financial Results for Quarter Ended September 30
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016 , to discuss ImmunoGen's
View HTML
Toggle Summary ImmunoGen Completes Strategic Review to Strengthen the Organization and Drive Long-Term Growth
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of a strategic review of its operations. As a result of this initiative, the Company will reduce its
View HTML